General Information of This Payload
Payload ID
PAY0OTRPA
Name
aHer2- (AL7-LP12)<sub>3.82</sub> Payload
Synonyms
aHer2- (AL7-LP12)<sub>3.82</sub> Payload
   Click to Show/Hide
Structure
Formula
C33H39FN6O7
Isosmiles
CC[C@@](C(C=C1C2=NC3=CC(F)=C(C)C(CC[C@@H]4NC(COCN(CCCCN)C(CN)=O)=O)=C3C4=C2CN51)=C(C5=O)CO6)(O)C6=O
InChI
InChI=1S/C33H39FN6O7/c1-3-33(45)21-10-25-30-19(13-40(25)31(43)20(21)14-47-32(33)44)29-23(7-6-18-17(2)22(34)11-24(38-30)28(18)29)37-26(41)15-46-16-39(27(42)12-36)9-5-4-8-35/h10-11,23,45H,3-9,12-16,35-36H2,1-2H3,(H,37,41)/t23-,33-/m0/s1
InChIKey
OHYSGQLHIPACSE-WYOOIXGGSA-N
Pharmaceutical Properties
Molecule Weight
650.708
Polar area
192.1
Complexity
1800.395724
xlogp Value
1.13092
Heavy Count
47
Rot Bonds
11
Hbond acc
11
Hbond Donor
4
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
aHer2- (AL7-LP12)3.82 [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.21 nM
Positive HER2 expression (HER2+++/++)
Method Description
Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.302 nM
Positive HER2 expression (HER2+++/++)
Method Description
Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.

   Click to Show/Hide
In Vitro Model Lung adenocarcinoma Calu-3 cells CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
3.14 nM
Positive HER2 expression (HER2+++/++)
Method Description
Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.

   Click to Show/Hide
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
355 nM
Negative HER2 expression (HER2-)
Method Description
Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.

   Click to Show/Hide
In Vitro Model Lung adenocarcinoma NCI-H1975 cells CVCL_1511
FelD1- (AL7-LP12)3.83 [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
121 nM
Positive HER2expression (HER2+++/++)
Method Description
Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.

   Click to Show/Hide
In Vitro Model Lung adenocarcinoma Calu-3 cells CVCL_0609
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
184 nM
Positive HER2expression (HER2+++/++)
Method Description
Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 400 nM Positive HER2expression (HER2+++/++)
Method Description
Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.

   Click to Show/Hide
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 400 nM Negative HER2 expression (HER2-)
Method Description
Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.

   Click to Show/Hide
In Vitro Model Lung adenocarcinoma NCI-H1975 cells CVCL_1511
References
Ref 1 Prodrugs of topoisomerase I inhibitor for ADC conjugations and methods of use thereof